Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA α2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers
- S. de Haas, S. D. de Visser, J. V. van Gerven
- Psychology, BiologyJournal of Psychopharmacology
- 1 June 2007
The results show that the effect profile of TPA023 differs markedly from that of Lorazepam, at doses that were equipotent with regard to effects on saccadic peak veLocity, and these differences reflect the selectivity of T PA023 for different GABAA receptor subtypes.
The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A 2,3 selective agonist, in comparison with lorazepam in healthy volunteers
- S. de Haas, K. Franson, J. V. van Gerven
- Psychology, BiologyJournal of Psychopharmacology
- 1 August 2009
This study showed that the three doses of SL65.1498 were well tolerated and induced no impairments on memory, sedation, psychomotor, and cognitive functions, which are believed to be mediated by the alpha1 and alpha5 subtypes.
Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAA α2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers
- S. de Haas, S. D. de Visser, J. V. van Gerven
- Psychology, BiologyJournal of Psychopharmacology
- 1 January 2008
Although less effect on VAs alertness was expected, diminished effects on memory and postural stability were present and clinical studies in anxiety patients should show whether this dose of MK-0343 is therapeutically effective with a different side-effect profile.
The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol
- S. de Haas, Rwm Zoethout, J. V. van Gerven
- BiologyJournal of Psychopharmacology
- 1 February 2012
This study showed that treatment with an α2,3 subunit-selective GABAA partial agonist was less effective than a stable level of alcohol in reducing ET symptoms, and provided no support for a therapeutic role of TPA023 in the suppression of ET symptoms.
MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers.
- J. D. Boot, S. de Haas, Z. Diamant
- Medicine, BiologyPulmonary Pharmacology & Therapeutics
- 1 June 2008